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Background: Favorable effects of formal pulmonary rehabilitation in selected moderate to severe COPD patients
are well established. Few data are available on the effects and costs of integrated disease management (IDM)
programs on quality of care and health status of COPD patients in primary care, representing a much larger group
of COPD patients. Therefore, the RECODE trial assesses the long-term clinical and cost-effectiveness of IDM in
primary care.
Methods/design: RECODE is a cluster randomized trial with two years of follow-up, during which 40 clusters of
primary care teams (including 1086 COPD patients) are randomized to IDM or usual care. The intervention started
with a 2-day multidisciplinary course in which healthcare providers are trained as a team in essential components
of effective COPD IDM in primary care. During the course, the team redesigns the care process and defines
responsibilities of different caregivers. They are trained in how to use feedback on process and outcome data to
guide implement guideline-driven integrated healthcare. Practice-tailored feedback reports are provided at baseline,
and at 6 and 12 months. The team learns the details of an ICT program that supports recording of process and
outcome measures. Afterwards, the team designs a time-contingent individual practice plan, agreeing on steps to
be taken in order to integrate a COPD IDM program into daily practice. After 6 and 12 months, there is a refresher
course for all teams simultaneously to enable them to learn from each other’s experience. Health status of patients
at 12 months is the primary outcome, measured by the Clinical COPD Questionnaire (CCQ). Secondary outcomes
include effects on quality of care, disease-specific and generic health-related quality of life, COPD exacerbations,
dyspnea, costs of healthcare utilization, and productivity loss.
Discussion: This article presents the protocol and baseline results of the RECODE trial. This study will allow to
evaluate whether IDM implemented in primary care can positively influence quality of life and quality of care in
mild to moderate COPD patients, thereby making the benefits of multidisciplinary rehabilitation applicable to a
substantial part of the COPD population.
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Chronic obstructive pulmonary disease (COPD) is a
smoking-related pulmonary disorder, characterized by
largely irreversible airflow obstruction, multisystemic
manifestations and frequent co-morbidities [1]. According
to current guidelines, stable COPD is managed with a
combination of different treatment components (e.g.
smoking cessation, physiotherapeutic reactivation, self-
management, optimization of medication adherence) [1],
involving different healthcare providers. Currently, treat-
ment is mostly guided by the severity of airflow limita-
tion [2]. However, COPD is a complex disease, with
great variation in symptoms, functional limitations and
co-morbidities as well as in progression towards more
severe stages [3]. Therefore, the existence of several
clinically relevant phenotypes calls for a more personal-
ized approach [4]. Ideally, optimal care of COPD patients
requires an individualized, patient-centered approach that
recognizes and treats all aspects of the disease, addresses
the systemic effects and co-morbidities, and integrates
medical care among healthcare professionals and across
healthcare sectors [5]. Since professional treatment, hos-
pital admissions and loss of work contribute to the eco-
nomic burden of disease worldwide, there is much interest
in systematically improving the quality of care, while redu-
cing total costs for patients with COPD and other chronic
illness. Integrated Disease Management (IDM) programs
have proliferated as a means of improving the quality and
efficiency of care [6].
The most frequently applied IDM programs in COPD
patients are pulmonary rehabilitation (PR) programs.
According to a Cochrane systematic review, the effect-
iveness of PR on exercise tolerance and quality of life is
well established [7]. In international reports and guide-
lines, it is acknowledged that PR is indicated for all
individuals with COPD who have decreased exercise tol-
erance, exertional dyspnea or fatigue, and/or impairment
of activities of daily living [1,8,9]. However, widespread
access is restricted, due to limited availability of resources
and high costs [10-12]. Furthermore, PR programs usually
include only the more severe patients and last only for a
limited period of time [13], while initial benefits seem to
decline over time [14-18]. After returning home, patients
are frequently insufficiently motivated to continue a more
physically active and healthy lifestyle. Unfortunately, gen-
eral practitioners (GPs) are rarely involved in PR programs
and, as a consequence, are often unable to support pro-
gram methods after a rehabilitation phase has formally
been concluded [13].
We previously argued that when components of PR
are integrated into a primary care IDM program, patients
can be treated in their home environment. Primary care
providers can then be (more) involved as direct coaches
of this process [19-21]. To establish such a program ofcombined interventions, the set-up of a multidisciplinary
team is vital, in which different healthcare professionals
participate and provide their share in the spectrum of the
required care (Figure 1). Ideally, patients and healthcare
providers are close partners in IDM, in order to better
control daily symptoms and promote self-management.
Furthermore, strong cooperation between several disci-
plines in primary care and mutually agreeable collabor-
ation with secondary and tertiary care are prerequisites
for integrated chronic care [19].
Systematic reviews of disease management for COPD
patients emphasise the need for well-designed, practical
multicenter trials [22,23], including broad representative
patient samples [24], with a wide range of physicians and
settings to improve external validity [23]. Furthermore,
authors of systematic reviews advocate studies designed
to evaluate the long-term effectiveness of IDM, [23] and
advise more health economic studies across different
care settings [24]. When considering the large number
of eligible patients for IDM in the community, the
potential impact is high. However, no trials have been
published that are specifically targeted to measure the
cost-effectiveness of IDM in patients recruited in
primary care.
Therefore, the aim of the current RECODE (acronym
for Randomized Clinical Trial on Effectiveness of inte-
grated COPD management in primary care) cluster
randomized clinical trial (NTR 2268) is to assess the cost-
effectiveness of an IDM program for COPD patients in
primary care in the Netherlands. Based on an earlier
controlled clinical trial evaluating the effect of an IDM
program in mild to moderate COPD, we found the
greatest improvements on quality of life in patients with
an MRC dyspnea score >2 [25]. As a result, we based
our sample size estimates on the a priori planned sub-
group of patients with MRC dyspnea score >2. This
article describes the design, rationale and baseline re-
sults of this trial.Methods/design
Study objective and design
The RECODE trial is a two-group parallel cluster-
randomized clinical trial with a two-year follow-up,
conducted in the primary care setting. Our objective is
to evaluate the clinical and cost-effectiveness of IDM for
COPD patients in primary care. The intervention is
delivered by the primary care team, including a GP, prac-
tice nurse, physiotherapist and dietician, with a consulting
pulmonary physician at hand. To avoid contamination
between treatment groups within practices, primary care
practices are randomized rather than patients. The
Medical Ethics Committee of the Leiden University
Medical Centre approved the trial.
Figure 1 Components of an Integrated Disease Management program for COPD patients in primary care.
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GPs
Inclusion of GPs and patients started in September 2010
and was finished in September 2011. Practices were
considered as candidates if they were willing to create
an integrated COPD management team, in which each
member has responsibility for their respective areas of
expertise. The practices had to include at least one GP,
one practice or extramural respiratory nurse, and one
physiotherapist specialized in COPD care. If multiple
practices were collaborating (for example with one prac-
tice nurse), they formed one cluster which was used for
randomization. Our recruitment goal was to enrol rep-
resentative groups of primary healthcare providers from
a broad spectrum of practices in order to enhance
external validity. This study was embedded in the Leiden
Primary Care Research Network (LEON), which is man-
aged by the department of Public Health and Primary
Care of the Leiden University Medical Center. This multi-
center research network consists of some 100 generalpractices in the western region of the Netherlands, in
which these practices signed an agreement to collaborate
in scientific research.
Patients
We included all patients who were diagnosed with
COPD by their treating physician. We selected patients
from electronic medical records (EMRs) of general prac-
tices. For all included patients, we attempted to verify
the diagnosis by lung function according to the GOLD
criteria [1]. If spirometry data were not available, patients
were invited to participate for a formal lung function
assessment, according to the ATS/ERS guidelines for
spirometry [26]. Exclusion criteria consisted of termin-
ally ill patients, dementia or cognitive impairment, in-
ability to fill in Dutch questionnaires, and hard drug
or alcohol abusers. We did not exclude patients if a
pulmonary physician was considered the main healthcare
provider. The GPs checked the selected patients against
the formal inclusion and exclusion criteria before the
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ten informed consent before participation in the study.Intervention
The intervention consists of an IDM program, which is
implemented by a multidisciplinary team in general prac-
tice. The team consists of at least three members: the GP,
the practice nurse, and a cooperating physiotherapist with
specific certified training in COPD care. Depending on the
team needs, a collaborating pulmonary physician and diet-
ician were added to the intervention team.
We trained the multidisciplinary teams of intervention
practices in a two-day course during 2010–2011. During
this course, essential components of IDM for effective
integrated COPD care in primary care were explained,
trained and rehearsed and supervised. Elements of this
course are further outlined in Table 1 and included a review
of the advice from international guidelines, performing/
interpreting spirometry and assessment of disease burden,
and motivational interviewing to stimulate a healthier
lifestyle including more physical activity and smoking
cessation. Furthermore, the healthcare providers were
trained in adopting self-management action plans, includ-
ing early recognition and treatment of exacerbations,
encouragement of regular exercise and guideline-based
physical reactivation, cooperation and collaboration with
secondary care, and instructions in dietician support for
nutritionally depleted patients. In addition, they were
trained in how to use feedback on process and outcome
data to guide and implement guideline-driven integrated
healthcare. This continuining medical education course
was developed according to recent national and inter-
national guidelines [1,27] and was provided by teachers
with hands-on experience with the program. At the end of
the course, the team designed a time-contingent individual
practice plan, agreeing on steps to be taken in order to in-
tegrate a COPD IDM program into daily practice. Inter-
vention practices were free in the fulfilment of their
individual plans, as long as they were feasible andTable 1 Components of IDM included in the RECODE course f
DM interventions Example
Optimal medication adherence Tailoring of advices from international
corticosteroids; daily respiratory comp
Proper diagnosis Performing and interpreting spiromet
Motivational interviewing Understanding and making use of pat
Smoking cessation counselling Review of the recent literature, discus
for smoking cessation
Applying self-management plans Teaching self-management technique
Guideline based physiotherapeutic
reactivation
Using a patients’ personal goal, referra
Dietary interventions Early recognition and treatment of nurelevant for the practice. After 6 and 12 months, there
was a refresher course for the intervention practices.
Web-based disease management application
During the course, the team learned the details of an ICT
program that supports recording of process and outcome
measures by access to a flexible web-based IDM applica-
tion, named Zorgdraad (in English ‘Care Ties’). This ap-
plication combined a patient and a healthcare provider
portal. The patient portal provided patients with disease-
specific easy written education, and allows personal goals
and personal notes. The healthcare portal left space for
a protocol for COPD follow-up guidance, quality of life
scores, physiotherapy follow-up and examination, smok-
ing cessation, medication records, and facilitates tailored
benchmark reports at 6 and 12 months. These reports
were generated by the researchers and sent to the prac-
tices to support prioritizing the healthcare needs. An
experienced instructor provided the practices during the
course with all information about Zorgdraad. An account
manager supported the practice nurse and GP on individ-
ual use of the program in daily practice. It was intended
that practice nurses give the COPD patients directions for
use on the patient-portal of Zorgdraad.
All practices were in essence free in the usage of
Zorgdraad, and in the fulfilment of their plans. Therefore,
not all patients received all components of the program,
but individual patient-specific care plans are negotiated by
the team, in collaboration with the patient. The intensity
of the IDM program depended upon the health status
and needs of the patient, resulting in some patients
receiving all interventions (e.g. smoking cessation, physio-
therapy, nutritional support), while stable patients only
had regular 6-monthly or 12-monthly follow-up by nurses.
Implementation of the intervention was assessed at
24 months (see “Outcomes”).
Financial coverage of the intervention
We arranged with the local healthcare insurer that all
RECODE patients with dyspnea on moderate or worseor multidisciplinary teams in primary care
guidelines, e.g. frequent exacerbations necessitate inhaled
laints necessitate long-acting bronchodilators
ry, assessment of disease burden using MRC and CCQ
ients’ personal goal in physical reactivation and lifestyle changes
sion of bottlenecks, applying behavioural techniques and drug therapy
s, including early recognition and treatment of exacerbations
l for physiotherapeutic reactivation in patients with MRC score >2.
tritionally depleted patients
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(MRC) score of >2) would be totally reimbursed for the
intervention, including physiotherapy.Usual care group
The control group consists of ‘usual care’ [28], which is
based on the 2007 national primary care COPD guide-
lines [27]. Instead of the multidisciplinary RECODE course,
the practice nurse received a course on technical perform-
ance of spirometry in primary care only, in order to divert
attention from any of the IDM topics mentioned in Table 1.
If the results of our study show that the IDM program
could substantially improve the health-related quality of
life of COPD patients, we will make the entire set ofTable 2 Overview of measurements per time point in the REC
Outcomes
Participants
Demographic characteristics
Lung function
Co morbidity
CCQ
SGRQ-C
EQ-5D
SF-36
Smoking behavior, guided smoking attempts
IPAQ
SMAS-30
MRC-Dyspnea scale
Exacerbations
Costs of health care utilization by patients, part A: Health care use Questionn
costs borne by patients/families
Costs of productivity loss: Absence from work Questionnaire
Costs of health care utilization by patients, part B: Data extraction from medi
medical treatment)
PACIC
Health care providers
ACIC
Satisfaction, involvement and implementation of the IDM program
IDM program information
Development costs of the IDM program
Implementation costs of the IDM program
Performance indicators of practices (see Table 4)
ACIC: Assessment Chronic Illness Care; CCQ: Clinical COPD Questionnaire; EQ-5D: Eu
Research Counsil scale; PACIC: Patient Assessment Chronic Illness Care; SF-36: Short
Management Scale-30.
IG = intervention group only.interventions available to the control group after the
study has been completed.
Outcomes
Time points
We follow patients at baseline, and at 6 and 12 months
with a face-to-face interview. Blinded research nurses
administer the questionnaires (Table 2) at specific time
points. These interviews take place at the general prac-
tice or at the patients’ homes, using the web-based
application Zorgdraad. At 9, 18 and 24 months we
sent questionnaires by post. In addition, retrospectively
the researchers extract data from the patients’ EMRs at
24 months over the complete trial period, regarding
prescribed medication.ODE study
Baseline 6
m
9
m
12
m
18
m
24
m
X
X
X
X X X X X X
X X X X X X
X X X X X X
X X X X X X
X X X X X X
X X X X X X
X X X X X X
X X X X X X
X X
aire, including direct non-medical X X X X X X
X X X X X X
cal records (health care utilization, X
X X X X X X
X X
X
(IG)
X
(IG)
X
(IG)
X X
roQol-5D; IPAQ: International Physical Activity Questionnaire; MRC: Medical
Form-36; SGRQ-C: Saint Georges Respiratory Questionnaire; SMAS-30: Self
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detect the clinically relevant effect of the intervention
[20,25]. Total study duration provides 24 months of
follow-up, to assess whether benefits can be maintained.
Patients
At baseline, we assessed socio-demographic factors (age,
gender, socioeconomic status measured through level of
education), marital status, lung function and co-morbidity.
Primary outcome
The primary outcome measure in this study is health
status as measured by the Clinical COPD Questionnaire
(CCQ) at 12 months. This questionnaire is a disease-
specific, 10-item questionnaire that calculates an overall
score and three domain scores: symptoms, functional
state and emotional state. Patients are required to respond
to each item on a 7-point scale with 0 representing the
best possible score and 6 representing the worst possible
score. This instrument is proven to be sensitive and valid,
and easy to administer in primary care. The minimal
clinical important difference (MCID) is −0.4 points [29,30].
Secondary outcomes
Secondary outcome measurements at 6, 9, 12, 18 and
24 months include (the questionnaire for each outcome
is provided in brackets):
1. Measures of changes in health-related quality of life
(disease-specific as well as generic), measured by :
a. CCQ
b. St. George Respiratory Questionnaire (SGRQ);
designed to measure health impairment in
patients with asthma and COPD. The first part
produces the symptom score and the second part
the activity and impact score. A total score can
also be calculated. We use a Dutch version of the
SGRQ, and consider a −4 unit change as the
MCID for within-group comparison [31].
c. The Euro Qol-5D-3L is a generic, preference-
based health-related quality of life questionnaire,
with many applications in respiratory disease. It
consists of 5 dimensions to describe health
(mobility, self-care, usual activities, pain/
discomfort, and anxiety/depression) each item
with three levels of functioning (e.g., no
problems, some problems, and extreme
problems). We used the value set derived from
the Dutch general population that, when applied
to the dimensions of the health state, result in a
preference-based utility score that typically ranges
from states worse than dead (<0) to 1 (full
health), anchoring dead at 0. Besides the
descriptive system and the off-the-shelf valuesets, the EQ-5D includes a visual analog scale
(VAS) where an individual rates his own health
on a scale from 0 (worse imaginable health) to
100 (best imaginable health) [32,33].
d. Short-Form Health Survey (SF-36) is a 36-item
questionnaire that measures two components
(physical and mental component). The physical
component consists of four domains of health:
physical functioning, role limitations due to
physical health, bodily pain and general health
perceptions. The mental component consists of
role limitations due to emotional problems,
vitality, social functioning and mental health [34].
2. Measures of change in patients’ lifestyle, illness
behavior and knowledge:
a. Smoking behavior, guided smoking attempts;
b. Taking initiatives, investment behavior and level
of self-efficacy, as measured by the Self-
Management Scale-30 (SMAS-30) [35];
c. Physical activity, as measured by the International
Physical Activity Questionnaire (IPAQ) short
form. This is an instrument designed primarily
for population surveillance of physical activity
among adults. The items in this short form are
structured to provide separate scores on walking,
moderate-intensity and vigorous-intensity activity.
The total score is computed by multiplying the
duration (in minutes) and frequency (days) of
walking, moderate-intensity and vigorous-
intensity activities by its energy requirement to
yield a score in Metabolic Equivalent Time
(MET) minutes.
3. Measures of change in intermediate patient-related
outcomes:
a. Dyspnea, measured by the MRC Dyspnoea
Scale [36].
b. Exacerbations: moderate (oral prednisone and/or
antibiotic courses), severe (hospitalizations).
These data were retrospectively extracted from
EMRs at 24 months, over the entire follow-up
period.
4. Measures of change in healthcare utilization and
costs:
a. Development and implementation costs of the
program: time and material resources associated
with the training of the healthcare providers and
the ICT support (measured at 24 months).
b. Costs of healthcare utilization by patients:
including all COPD and non-COPD related cost
of a) hospitalization, b) medication, c) caregiver
contact, and d) revalidation.
Retrospectively we extract data from EMRs at
24 months over the complete trial period,
regarding prescribed medication.
Table 3 Characteristics of included primary care practices
in the RECODE study
General practices
Number of GP practices 54
Number of clusters 40
Number of included patients per
participating cluster, range
11-79
Type of practice,%
Single-handed practice 44
One or more partner practice 41
Healthcare centre 15
Practice location,% urban 72
Patient practice population, n (range) 3418 (1750-16907)
Ethnic minorities,% 15
General practitioners
Number of participating GP’s 76
Gender GP,% male 61
Age GP, years (range) 50 (35-62)
Years practicing, years (SD) 16 (8.2)
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families, e.g. travel costs. Costs of productivity
loss due to absenteeism/presenteeism at work.
This was measured at baseline, and at 6, 9, 12, 18
and 24 months.
5. Measures of change in care delivery process: level of
care integration according to patients, measured by
the Patient Assessment Chronic Illness Care
(PACIC) [37]. This questionnaire was self-reported
by patients in both groups and was administered at
baseline, and at 6, 9, 12, 18 and 24 months.
Healthcare providers
The Assessment Chronic Illness Care (ACIC) question-
naire, which is a tool to measure the level of care inte-
gration according to healthcare providers [38], was sent
to primary care providers at baseline and is evaluated at
12 months. Furthermore, we use a self-designed ques-
tionnaire at 12 months (“Satisfaction, involvement and
implementation of the IDM program”) for the primary
care team, to measure the level of involvement and im-
plementation of the practice teams with the RECODE
intervention at 12 months. This questionnaire comprises
questions on the number and type of healthcare pro-
viders which were involved in the program, the types
of team meetings and local appointments, and the usage
of tailored benchmark reports. Furthermore, we requested
the number of patients involved in the intervention,
and the numbers of components implemented in daily
practice. Overall, the healthcare providers are asked to
rate the intervention on a 5-point scale, and we ask for
details on possible bottlenecks and problems regarding
implementation.
Current level of care of the practices at baseline
The current level of COPD care was assessed at baseline
in all general practices to be able to report any difference
in quality of care at 12-months follow-up. Therefore,
from the EMRs we extracted the following performance
indicators: registration of smoking status and stop-smoking
advice, registration of body mass index, assessment of
spirometry and inhalation technique in the last year,
the number of patients with monitored functioning by
means of the CCQ, MRC, or the number of patients
with controlled physical activity in the last year.
Sample size calculation
The primary outcome is the difference in change in the
CCQ score between baseline and 12 months between
both groups. We used methods for standard sample size
estimates for trials that randomised at the level of the
individual [39] adjusting for clustering by inflating sam-
ple size estimates by the design effect given by 1 + (n-1)ρ,
where n is the average cluster size, and ρ is the estimatedintraclass correlation coefficient (ICC) [40]. Sample size
estimates are based on the mean difference in CCQ
between intervention and control group. Using the min-
imal clinically important mean difference for the CCQ
[29], and the upper value of 0.05 from a range of ICC
values identified in studies involving the older person
in primary care [41], power calculations indicate that
40 clusters of practices with an average of 27 participants
per cluster are required. To allow for subgroup analysis
in MRC scores 1–2 versus 3–5, in total 1080 partici-
pants are need to be randomized to achieve a power of
at least 80% with alpha levels of 0.05, including a par-
ticipant loss to follow-up of 10% or a loss of 4 clusters
at 12 months.
Randomization
Cluster randomization was at the level of the primary
care team. The first author recruited the practices, and
the selected participants were checked by the GP against
formal inclusion and exclusion criteria before the inter-
vention started. To enhance comparability between the
intervention and control group, the clusters were matched
and randomized by a researcher who was blinded to
the identity of the practices. Matching was into pairs
according to the following criteria: (i) percentage of
patients from ethnic minorities, (ii) type of practice,
(iii) practice location (urban/rural), (iv) age of GP, and
(v) gender of the GP. Subsequently, the matched prac-
tices were randomized to the intervention group or
the control group by using a computer-generated ran-
dom number list.
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Informed consent was provided by the GPs and the
patients. The informed consent was acquired before
the course took place and the practices started with
their intervention.
Blinding
Because of the nature of the intervention, it is not possible
to blind patients and primary care providers to practice
group allocation. Therefore, blinded research nurses assess
the outcomes. Patients are instructed not to report on
their type of management to the outcome assessors.
Data analysis at baseline
Non-participation analysis at baseline
We recruited potential participants with an invitation
letter including a postal CCQ questionnaire. Returned
questionnaires were analysed to investigate if there were
differences between participants and patients who ful-
filled inclusion criteria, but refused to participate in
the trial (non-participants). We compared differences
on CCQ scores, sex and age using independent t-tests
and chi-square tests.
Analysis plan
Analysis of effectiveness at 12 and 24 months
The final analysis of the trial will be carried out on an
intention-to-treat basis. The freedom of the clusters to
fill in the precise implementation of the intervention will
probably relate to the (cost)-effectiveness of the inter-
vention and, therefore, the clustering of patients in GP
practices should be taken into consideration in the ana-
lysis [42]. Therefore, the results will be investigated with
respect to the differences in intensity between and within
clusters over time using multi-level analysis.
Pre-planned subgroup analyses
We will study the influence of age, sex, disease burden
(MRC score 1–2 vs. 3–5), disease severity (GOLD stage),
and socioeconomic status. The trial was specifically poweredTable 4 Description of current level of care of included GP pr
practices
Measurement category Process indicator
Smoking % RECODE patients with registered smoking s
% RECODE patients that are registered smoker
%RECODE patients, which are registered smok
BMI % RECODE patients of which the BMI is measu
Treatment & monitoring % RECODE patients with inhalation technique
% RECODE patients with a spirometry test in t
% RECODE patients with monitored functionin
% RECODE patients with controlled physical aon the MRC 1–2 vs. 3–5 subgroup analyses; see ‘Sample
size calculation’.
Economic evaluation at 12 and 24 months
The economic evaluation will be performed according to
the internationally agreed guidelines [43] and the national
guidelines for pharmacy-economic research [44]. We will
calculate the costs from a healthcare perspective and a
broad societal perspective, in order to facilitate decision
making. The healthcare perspective will include all costs
covered by the healthcare sectors budget: development,
implementation and healthcare utilization costs. The
costs from societal perspective will include travel and
productivity costs in addition to the costs from the
healthcare perspective to capture (almost) all costs re-
lated to the intervention, irrespective of who actually
bears them.
The healthcare utilization costs (excluding medication
costs), travel costs and productivity costs of patients will
be calculated using questionnaires at different time points
(Table 2). These questionnaires will collect self-reported
cost-related data by patients using a recall period of three
months. Additionally, the type and amount of medication
from the individual patients will be collected from the
GP information systems. The unit costs per medication
prescription will be based on the GIP Databank [44].
Time and material resources associated with the train-
ing of the healthcare providers, the multidisciplinary
team meetings in the GP practices, and the ICT support
will be estimated based on course attendance, computer-
documented minutes of ICT use, treatment plans, and
professional self-report. Finally, the productivity costs
will be estimated using the friction method, which im-
plies that the costs of absenteeism will occur only for a
fixed (friction) period ending at the moment that the
employee is replaced [45].
Cost-effectiveness (CEA) and cost-utility analyses (CUA)
The relation between the costs and the estimated health
outcomes is expressed in cost-effectiveness ratios: (1) costsactices: distribution of the performance indicators of the
% (SD)
tatus 53 (27.9)
s 35 (19.3)
ers with stop-smoking advice in the last year 35 (34.3)
red in the last year 42 (23.8)
controlled in the last year 13 (20.3)
he last year 12 (14.9)
g with a structured method ( CCQ or MRC) in the last year 28 (27.4)
ctivity in the last year 30 (24.9)
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per patient with a clinically relevant improvement of at
least 0.4 units on the CCQ, (4) costs per patient with a
clinically relevant (4 units) improvement on the SGRQ,
and (5) costs per patient with a 1 point improvement
on the MRC dyspnea scale. Adopting such a wide range
of outcome measures in the economic evaluation is in
line with recent guidelines of a joint ATS/ERS task force
on outcome measurements in COPD that recommend
taking a multi-outcome approach [46]. At the sameRand
Intervention
20 clusters
N=1488 sele
patients
Excluded by GP (N=333):
* Not meeting inclusion criteria (n=301):
- terminally ill (n=45)
- dementia (n=76)
- cognitive impairment/addicts (n=15)
- no COPD (n=165)
* Died (n=9)
* Other (n=23)
En
ro
llm
en
t
Fo
llo
w
-u
p
N=1155 invi
patients
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Figure 2 Flowchart of the recruitment to the baseline assessment oftime, comparison with the cost-effectiveness of other
interventions for other diseases is made possible through
the calculation of costs per QALY. Uncertainty around
cost-effectiveness ratios will be dealt with in probabilistic
sensitivity analysis in which costs and health outcomes
will be bootstrapped and plotted on cost-effectiveness
planes from which cost-effectiveness acceptability curves
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[50] will be calculated using different thresholds of the
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cted 
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the RECODE study.
Table 5 Characteristics and comparison of participants
and non-participants of the RECODE trial
Participant
(n = 961)*
Non-participant
(n = 588)
p-value
Age, years (SD) 68.7 (11.0) 67.8 (11.5) 0.162
Males,% 54.7 46.9 0.003
CCQ
Symptoms 2.4 (1.2) 1.9 (1.2) <0.001
Functional state 1.8 (1.3) 1.5 (1.4) <0.001
Mental state 0.9 (1.2) 0.7 (1.2) <0.001
Total score 1.9 (1.1) 1.5 (1.1) <0.001
*Values are means (S.D.) unless stated otherwise. ** Of the 1086 RECODE
patients, there were 961 CCQ questionnaires available at the time of
initial invitation.
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http://www.biomedcentral.com/1471-2466/13/17which patient, practice and team characteristics are related
to the size of the net monetary benefits. The economic
evaluation will compare differences in costs to differences
in effects (CEA) and quality adjusted life-years (CUA).
The analysis will have a 12 and 24-months time horizon.
Sensitivity analyses will be performed on the perspective
(societal versus healthcare) and the applied utility measure
(Dutch EQ5D).
Baseline results
Primary care practices
The characteristics of the enrolled 54 general practices,
which formed 40 clusters, are shown in Table 3. Num-
bers of included patients per participating cluster ranged
from 11 to 79 patients. Most practices were single-handed
(44%) or one or more partner practices (41%). The en-
rolled practices included a total of 76 participating GPs;
the majority (61%) were males with a mean age of 50
(range 35–62) years and 16 (SD 8.2) years of practicing.
Current level of care of the practices
We assessed the current level of COPD care at baseline
in all general practices to be able to report any difference
in quality of care after 12 months. Results at baseline are
shown in Table 4. Almost half of the RECODE patients
(53%) have a registered smoking status; however, a stand-
ard spirometry test in the last year was less common, with
only (12%) of the patients receiving spirometry.
Patient recruitment
Figure 2 shows the study flow chart until baseline. In
total, 2886 patients were selected in 40 clusters of which
617 (21%) patients were excluded by their GP. Most of
these excluded patients were registered as a COPD pa-
tient in the EMR; however, after evaluation they turned
out to be mislabelled by their GP. After exclusion, 2269
patients were invited to participate, of which 48% partic-
ipated (response 48%). Most patients indicated no reason
for refusing (71%), while others expressed no interest
(16%), did not consider themselves to be a COPD pa-
tient (6%), or reported not having troublesome COPD
symptoms (6%). In total, we have been able to allocate
1086 COPD patients at baseline: 554 participants to the
intervention group and 532 participants to the control
group. Patients were included from September 2010
until September 2011.
Non-participation analysis
As we invited all eligible participants for this trial with
an invitation letter with an attached CCQ questionnaire,
we were able to determine any differences between
participants of the trial and COPD patients eligible but
declining randomization, in order to assess external val-
idity (Table 5). Of all eligible patients who were invitedto participate, 1549 questionnaires had analyzable data.
We received a higher response rate (961 vs. 588) of
returned CCQ questionnaires in the group of patients
willing to participate in the trial, compared to patients
eligible but declining randomization. There was no dif-
ference in age between both groups. Significantly more
men (54.7%) are participating in the RECODE trial com-
pared to the proportion of men in patients who declined
participation (46.9%). Furthermore, participants in the
trial reported significantly more symptoms and disabil-
ities on their functional and mental state, which was
reflected in a mean total CCQ score of 1.8 (1.1), com-
pared to 1.5 (1.1) in non-participants.
Baseline characteristics COPD patients
Table 6 presents the baseline demographic and clinical
characteristics of the included COPD population. En-
rolled subjects were mainly elderly (ex) smokers, and
had moderate COPD which is reflected by a mean post-
bronchodilator FEV1 of 68% predicted. We included
COPD patients with substantial co-morbidities: 36.8%
had a diagnosis of hypertension, 16.1% suffered from
major cardiovascular disease, 14.7% had diabetes and
9.9% had a combined diagnosis of depression. Mean
SGRQ total score was 35.6 (20.5) and mean CCQ total
score was 1.5 (0.97). The proportion of patients with
dyspnea on moderate exertion or worse (MRC score >2)
comprised one third of the study population.
Discussion
Optimal COPD management continues to be an import-
ant area of research, as the worldwide prevalence is
growing and costs will rise in coming decades. Further-
more, in contrast to asthma patients, medication has
demonstrated to have limited effect in the management
of COPD patients. IDM for chronic diseases has the
potential to influence health status, while reducing total
costs [6]. However, the (cost) effectiveness of IDM in
primary care COPD patients remains unknown, due to
Table 6 Baseline demographic and clinical characteristics
of the patients with COPD included in the RECODE study
Total (n = 1086)
Men,% 53.9
Age, y 68.3 (11.2)
Employment,% 28.3
Low education,% 40.3
Pulmonary function1
Predicted FEV1**% 67.8
FER***% 57.7
GOLD-stage,%****
I Mild 24.6
II Moderate 53.2
III Severe 19.4
IV Very severe 2.9
Smoking status,%
Current 36.7
Former 53.2
Never 10.1
Co-morbidities
Major cardiovascular disease,% 16.1
Hypertension,% 36.8
Diabetes,% 14.7
Depression,% 9.9
Charlson co-morbidity index 2.3 (1.3)
CCQ
Symptoms 2.09 (1.21)
Functional state 1.40 (1.22)
Mental state 0.51 (0.98)
Total score 1.50 (0.97)
MRC
score ≤2.% 66.6
score >2.% 33.4
MRC score (mean) 2.01 (1.28)
SGRQ
Symptom 50.5 (20.9)
Activity 47.8 (29.5)
Impact 23.3 (19.6)
Total 35.6 (20.5)
EQ-5D
Total score 0.74 (0.26)
EQ-VAS 67.0 (17.4)
SF-36
Physical 38.3 (10.8)
Mental 48.6 (10.4)
Table 6 Baseline demographic and clinical characteristics
of the patients with COPD included in the RECODE study
(Continued)
IPAQ
Total MET minutes 2925 (4683)
High physical activity,% 11.1
Moderate physical activity,% 0.6
Low physical activity,% 88.4
Self-management
Taking initiatives 57.0 (17.9)
Investment behavior 60.4 (17.6)
Self-efficacy 65.3 (17.4)
*Values are means and corresponding standard deviations (SD) unless stated
otherwise. **FEV1 predicted: Forced expiratory volume in 1 second, post-
bronchodilator, predicted according to age and height. ***FER: forced
expiratory ratio (FEV1 / FVC x 100%), FVC: forced vital capacity. ****Mild = FEV1
> 80%, Moderate = 50% ≤ FEV1 < 80%, Severe = 30% ≤ FEV1 <50%,
Very severe = FEV1 < 30%
1. Lungfunction was missing in 66 patients (34 control patients; 32
intervention patients).
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http://www.biomedcentral.com/1471-2466/13/17a paucity of randomized clinical trials in this field. This
article presents the design and baseline results of the
RECODE trial, which aims to assess the (cost) effective-
ness of IDM for COPD patients in primary care.
We have chosen a cluster-randomized design to prevent
cross-contamination of the IDM intervention within a
practice. In order to enhance comparability between the
intervention and control group at baseline, clusters were
matched by stratification and randomized by a blinded
researcher. We were able to allocate a broad sample of
1086 COPD patients (ranging from mild to very severe
patients) with a response rate of participants of almost
50%. We can conclude from our non-participation ana-
lysis that we have recruited a sufficient proportion of
patients with considerable complaints, and thus room
for improvement. Furthermore, the included practices
showed great diversity in the kind of practice, practice
size and distribution of ethnic minorities, thereby con-
tributing to high external validity.
To date, previous clinical trials of disease management
or home-based rehabilitation trials in primary care have
revealed encouraging results on quality of life [51-55].
Based on an earlier example of a published protocol [56],
we compared several aspects of our current study to the
previously conducted randomized trials which aimed to
evaluate the effectiveness of such programs in primary
care or in the home-based setting (Table 7).
Selection of patients
In respiratory medicine there is a lack of research on
mild to moderate COPD patients, despite that over 80%
of COPD patients suffer from this stage of disease and
are often treated in primary care. Moreover, it has been
able 7 Characteristics of trials evaluating IDM programmes in primary care or home-based setting
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http://www.biomedcentral.com/1471-2466/13/17shown that treatment decisions for asthma and COPD
patients are usually based on studies including a very
small and highly selected proportion of the real patient
population; this indicates the need for more real-life
studies targeted at the true population, and applying less
exclusion criteria [57]. Former trials included a highly
selected severely ill patient population [51,52] or recruited
their patients in secondary care [55]; overall, this is not an
uncommon phenomenon in primary care COPD trials.
Limited follow-up
Most studies presented data up to 12 months follow-up,
while limited information is available on studies with
long-term (18 or 24 months) follow-up. Gottlieb et al.
evaluated the effect of an intensive exercise and educa-
tional program in patients with moderate COPD during
18 months of follow-up [53]. Although an effect was
found on walking distance and quality of life, the effect
on quality of life disappeared over 18 months. However,
this result should be interpreted with caution, as the
intensive rehabilitation program lasted only 7 weeks,
which was followed by a maintenance phase including
a monthly session focusing on ways of incorporating
exercise in daily life. Furthermore, the authors acknowledged
many dropouts before randomization, at randomization
and during rehabilitation, potentially introducing bias and
indicating substantial loss of power [53]. Another study
evaluated the efficacy of a community-based COPD man-
agement program in less advanced (GOLD 2 and 3)
COPD patients during 24 months follow-up. The SGRQ
score initially improved in the intervention group com-
pared to the control group. At 12 months, scores in the
intervention group had returned to baseline, whereas in
the usual care group it remained stable up to 12 months
and worsened thereafter [55].
Methodological aspects
Due to the nature of the intervention, blinding of partic-
ipants and patients to the intervention is usually impos-
sible. However, blinding of an outcome assessor can
substantially diminish the risk of bias. All the above-
mentioned studies, except for the trial of Wetering et al.
[55], failed to introduce blinded outcome assessors or
did not report this as such. In the study of Rea et al.
[54], randomization was also clustered, comparable to
our study; however, statistical analysis was at the level of
the patient, thereby not taking the clustering coefficient
in account. Furthermore, the authors failed to allocate
five practices to the correct treatment group.
Planned subgroups
Finally, this study differs from the other studies in that
we based our sample size estimates on the a priori planned
subgroup of patients with an MRC dyspnea score >2. Weearlier reported that we found the greatest improvements
on quality of life in these patients [25]. It is probably
that lung function is still relatively well maintained at
this stage, while patients experience considerable dys-
pnea and an impaired quality of life [20]. As a result of
this pre-planned subgroup power analysis and to com-
pensate for the intra-clustering, we allocated almost
1100 patients in the present trial according to protocol.
As can be seen in Table 7, this number is much higher
than that of earlier studies in this field.
Conclusion
It is acknowledged that not all patients who potentially
benefit from an exercise training program, pulmonary
rehabilitation, or smoking cessation intervention are
actually receiving this type of support in daily practice.
It is likely that costs will be lower when patients are
detected and persuaded to change their lifestyle at an
earlier stage, possibly reducing health decline and dis-
ease progression in the long term. To the best of our
knowledge, this is the first and largest cluster random-
ized trial to evaluate the cost and clinical effectiveness
of IDM in primary care COPD patients. The results of
this study will provide insight into the clinical and cost-
effectiveness of IDM in primary care COPD patients,
also on the long term.
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